First-of-Its-Kind Nasal Spray Approved

The US Food and Drug Administration (FDA) has approved the first nasal spray of its kind to treat a condition related to diabetes.

This new approval is for Gimoti (metoclopramide). The FDA approved it to treat adults with diabetes who have irregular or slow stomach emptying (gastroparesis).

The active ingredient metoclopramide has been on the market since 1979 and has been found under the name Reglan.

Metoclopramide has only been available in tablet form, as an injection, as orally disintegrating tablets and in an oral solution — until now.

Metoclopramide is now available in a nasal spray. Treatment is typically between two and eight weeks.

The key difference? Nasal administration bypasses the stomach and allows for absorption even if there are issues with slow stomach emptying.

The recommended dose is one spray (15 mg) in one nostril four times per day. It's to be used 30 minutes before each meal and at bedtime for a maximum of four sprays a day.

Common side effects of Gimoti included unpleasant taste after use, headache and feeling tired.

A potential serious side effect is the risk for tardive dyskinesia, which is abnormal muscle movements (mostly in the face muscles). Tell your health care provider right away if you notice any movements you cannot control, such as lip smacking, puckering up your mouth, frowning or sticking out your tongue.

Tell your doctor about all the medications you take, including prescription drugs, over-the-counter medications, and herbal and nutritional supplements. Metoclopramide may interact with other medications.

Do not drink alcohol if you are taking this medication.

Speak with your health care provider if you have any questions.